Back to top
more

MediWound (MDWD)

(Real Time Quote from BATS)

$15.80 USD

15.80
12,662

+0.16 (1.02%)

Updated Nov 19, 2024 01:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omega Therapeutics (OMGA) delivered earnings and revenue surprises of -3.45% and 109.63%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 17.65% and 2.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -56.82% and 26.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 27.55% and 38.41%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Reports Break-Even Earnings for Q3

by Zacks Equity Research

Ardelyx (ARDX) delivered earnings and revenue surprises of 100% and 13.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of -61.90% and 0.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -1.69% and 11.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

AST SpaceMobile (ASTS) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

AST SpaceMobile (ASTS) is expected to report top-line growth year over year in the second quarter of 2024, backed by healthy demand in several sectors.

PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -16% and 2.82%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Harrow (HROW) delivered earnings and revenue surprises of 48% and 14.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

MediWound (MDWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength in Kidney Care Likely to Aid DaVita's (DVA) Q2 Earnings

by Zacks Equity Research

Improvement in RPT and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the second quarter.

Product Demand Likely to Aid Organon's (OGN) Q2 Earnings

by Zacks Equity Research

Continued solid uptake of Organon's (OGN) products is expected to have driven second-quarter revenues.

Can MediWound (MDWD) Climb 57.49% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 57.5% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 2.50% and 6.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

OptiNose (OPTN) delivered earnings and revenue surprises of -20% and 6.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of 52.63% and 0.25%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Century Therapeutics (IPSC) delivered earnings and revenue surprises of 10% and 185%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?

by Zacks Equity Research

MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for MediWound (MDWD) points to a 76.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

What Makes MediWound (MDWD) a Good Fit for 'Trend Investing'

by Zacks Equity Research

MediWound (MDWD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 17.39% and 0.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?

by Zacks Equity Research

MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -15.63% and 7.58%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD)'s Technical Outlook is Bright After Key Golden Cross

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?